Items Tagged ‘Stage IV Melanoma’

October 11th, 2016

Epacadostat Plus Keytruda® Appears Effective in Melanoma

By

The treatment combination consisting of epacadostat plus Keytruda® (pembrolizumab) appears effective in the treatment of advanced melanoma. Melanoma is a type of skin cancer that often starts in the form of a mole. If detected and treatable with surgery, melanoma has a high cure rate. However, once melanoma invades deeper tissues or spreads from its […]

View full entry

Tags: advanced, Epacadostat, keytruda, Melanoma, mole, News, Skin Cancer, Stage III Melanoma, Stage IV Melanoma


September 20th, 2016

Cotellic®/Zelboraf® Combo: New Standard of Care for Melanoma

By

The treatment combination consisting of Cotellic® (cobimetinib) plus Zelboraf® (vemurafenib) improves overall survival for patients with advanced, BRAF (V600) mutation-positive melanoma. These confirmatory results have led to this treatment combination being considered as a new standard of care for patients with this disease. These results were recently published in the Lancet Oncology. Melanoma is a […]

View full entry

Tags: advanced, BRAF V600, cobimetinib, combination, Melanoma, metastatic, News, Stage III Melanoma, Stage IV Melanoma, vemurafenib


July 21st, 2016

3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma

By

Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those treated with Taflinar only. These results were presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Advanced melanoma refers to skin […]

View full entry

Tags: 2016, advanced, asco, BRAFV600E/K mutation, COMBI-d trial, dabrafenib, kinase inhibitors, mekinist, Melanoma, News, Stage IV Melanoma, Taflinar


December 2nd, 2015

Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma

By

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which Opdivo has been approved in the past 12 months. The indication for this expanded approval specifies that Opdivo can be used for treatment […]

View full entry

Tags: advanced, CheckMate -066 trial, Melanoma, metastatic, News, opdivo, Skin Cancer, Stage III Melanoma, Stage IV Melanoma


June 29th, 2015

Opdivo® Alone or Combined with Yervoy® Effective in Advanced Melanoma

By

Opdivo® (nivolumab) used alone or in combination with Yervoy® (ipilimumab) appears to extend progression-free survival in patients with advanced melanoma. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the New England Journal of Medicine. Standard treatment for advanced melanoma typically […]

View full entry

Tags: advanced melanoma, ipilimumab, Melanoma, News, nivolumab, opdivo, Stage III Melanoma, Stage IV Melanoma, Yervoy


May 1st, 2015

Melanoma Drug T-VEC Receives Recommendation for FDA Approval

By

An advisory panel to the U.S. Food and Drug Administration (FDA) has recommended approval of the investigational drug T-VEC (talimogene laherparepvec) for the treatment of metastatic melanoma. Biopharmaceutical company Amgen recently announced plans to move forward with approval process.[1] The recommendation for approval is based on findings from a Phase III clinical trial in which […]

View full entry

Tags: fda, Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, T-VEC


April 20th, 2015

Keytruda® May Be More Effective than Yervoy® in Advanced Melanoma

By

Keytruda® (pembrolizumab) appears to outperform Yervoy® (ipilimumab) at initial treatment of patients with advanced melanoma. Pharmaceutical company Merck announced these Phase III clinical trial findings in a press release in March 2015. Melanoma is less common than non-melanoma skin cancer, but tends to be much more aggressive. What makes melanoma so dangerous is that it […]

View full entry

Tags: advanced melanoma, ipilimumab, KEYNOTE-006, keytruda, Melanoma, News, pembrolizumab, Stage III Melanoma, Stage IV Melanoma, Yervoy


February 2nd, 2015

Coffee May Decrease Risk of Melanoma Skin Cancer

By

Coffee might do more than perk you up. New research suggests that coffee drinkers are less likely to develop malignant melanoma, and their risk decreases with every cup they drink.1 Coffee has long been associated with a reduction in the risk of various cancers however the current study is the first to show a reduction […]

View full entry

Tags: coffee, Melanoma, melanoma prevention, News, Recurrent Melanoma, Stage IV Melanoma


December 23rd, 2014

FDA Approves Nivolumab for Advanced Melanoma

By

The FDA granted accelerated approval to nivolumab (Opdivo) for patients with unresectable or metastatic melanoma who no longer respond to other drugs. Nivolumab, a PD-1 inhibitor, is intended for patients who have been previously treated with ipilimumab (Yervoy) and, for melanoma patients whose tumors express the BRAF V600 mutation, for use after treatment with ipilimumab […]

View full entry

Tags: fda, Melanoma, News, nivolumab, opdivo, PD-1, Recurrent Melanoma, Stage IV Melanoma


December 8th, 2014

Yervoy® May be Beneficial in Uveal Melanoma

By

The first trial of the immunomodulator Yervoy® (ipilimumab) conducted in patients with uveal melanoma appears promising in according to the results of a small clinical trial presented at the recent Society of Melanoma Research (SMR) 2014 International Congress, in Zurich, Switzerland. Uveal melanoma is the most common cancer of the eye in adults, and the […]

View full entry

Tags: ipilimumab, Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, uveal melanoma, Yervoy


November 25th, 2014

PV-10 Injection is Promising Treatment of Melanoma Lesions

By

The results of an international clinical trial evaluating the use of intralesional rose bengal (PV-10), injected in 80 patients with refractory cutaneous or subcutaneous metastatic melanoma were recently reported. PV-10 is a 10% solution of Rose Bengal, which was originally used as an agent to stain necrotic tissue in the cornea. Its potential use in […]

View full entry

Tags: intralesional, Melanoma, News, pv-10, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, Stages I-II Melanoma, subcutaneous


November 24th, 2014

New Information Helps Understanding Immunotherapy’s Successes—And Its Failures

By

(OMNI- CancerConnect) A collaborative team of leaders in the field of cancer immunology from Memorial Sloan Kettering Cancer Center has made a key discovery that advances the understanding of why some patients respond to ipilimumab, an immunotherapy drug, while others do not.  MSK was at the forefront of the clinical research that brought this CTLA-4 […]

View full entry

Tags: immunotherapy, ipilimumab, Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, Yervoy


November 20th, 2014

Nivolumab Superior to Chemotherapy in First Phase III Trial as Initial Treatment in Advanced Melanoma

By

The immunotherapy drug nivolumab produces significantly better overall survival than chemotherapy as initial treatment in advanced melanoma, according to findings from its first Phase III study in previously untreated patients. These results were recently published online in the New England Journal of Medicine.[1] Of the more than one million new diagnoses of skin cancer each year, […]

View full entry

Tags: immunotherapy, Melanoma, melaoma, News, nivolumab, PD-1, Recurrent Melanoma, Stage IV Melanoma


November 14th, 2014

Progress in the Treatment of Advanced Melanoma and Other Skin Cancers

By

By one estimate, over the past three decades more people in the United States have had skin cancer than all other cancers combined.1 According to the American Cancer Society, 3.5 million cases of basal and squamous cell skin cancer are diagnosed each year.2 Rates of melanoma—the deadliest form of skin cancer—are on the rise,2 particularly […]

View full entry

Tags: anti-PD-1, basal cell, General Skin Cancer, keytruda, Melanoma, News, pembrolizumab, Recurrent Melanoma, Skin Cancer, Skin Cancer Overview, Stage III Melanoma, Stage IV Melanoma


November 12th, 2014

Immune Booster Combined with Checkpoint Blocker Improves Survival in Metastatic Melanoma

By

(CancerConnect) Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer – a median 17.5 months vs. 12.7 months – if they simultaneously received an immune stimulant, according to a study led by Dana-Farber Cancer Institute scientists. Patients in the clinical trial who got the combined therapies also […]

View full entry

Tags: gm-csf, ipilimumab, Melanoma, News, Recurrent Melanoma, sargramostim, Stage IV Melanoma, Yervoy